Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.52 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.39 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.39 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.34 |
| ▸ | GRM8 | O00222 | 1/20 | 0.34 |
| ▸ | GRM6 | O15303 | 1/20 | 0.34 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.34 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.34 |
| ▸ | GSR | P00390 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.34 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.34 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.34 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28571398 | 1.00 | ALOX15 (0.52) | ALOX15BLMPMP22KMT2ADPP4 | |
| SCHEMBL711607 | 0.92 | ALOX15 (0.60) | ALOX15BLMPMP22KMT2ADPP4 | |
| SCHEMBL2443865 | 0.91 | KMT2A (0.68) | ALOX15BLMPMP22KMT2ADPP4 | |
| SCHEMBL9452863 | 0.89 | ALOX15 (0.48) | ALOX15BLMPMP22KMT2ADPP4 | |
| SCHEMBL5187828 | 0.89 | ALOX15 (0.39) | ALOX15BLMPMP22KMT2ADPP4 | |
| SCHEMBL17559225 | 0.88 | ALOX15 (0.42) | ALOX15BLMPMP22KMT2ADPP4 | |
| SCHEMBL869883 | 0.86 | ALOX15 (0.50) | ALOX15BLMPMP22KMT2ADPP4 | |
| SCHEMBL5524401 | 0.85 | ALOX15 (0.48) | ALOX15BLMPMP22KMT2ADPP4 | |
| SCHEMBL3178198 | 0.84 | ALOX15 (0.52) | ALOX15BLMPMP22KMT2ADPP4 | |
| SCHEMBL1674762 | 0.84 | SLC1A1 (0.54) | ALOX15BLMPMP22KMT2ADPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117969859-A | Metabolic biomarker for polycystic ovary syndrome and application thereof | 山东大学 | 2024-05-03 | — | — | CN | claimed |
| US-20090269806-A1 | PROCESS FOR PRODUCING DIPEPTIDES | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-10-29 | — | — | US | claimed |
| WO-2003002135-A2 | HERBAL COMPOSITION | PRETORIUS ANDRIES PHILIPPUS (ZA) | 2003-01-09 | — | — | WO | claimed |
| EP-0514509-B1 | COMPOSITION AND ITS PREPARATION PROCESS USING ANTIGEN CONJUGATED TO ENZYMATIC ACTIVITY FOR IMMUNOLOGICAL DIAGNOSIS AND CHAGAS' DISEASE IMMUNOLOGICAL DIAGNOSIS KITS, FOR INDIVIDUAL AND EPIDEMIOLOGICAL APPLICATION, BASED ON THAT COMPOSITION | FUNDACAO OSWALDO CRUZ (BR) | 2000-09-20 | — | — | EP | claimed |
| US-12583896-B2 | Caged-degron-based molecular feedback circuits and methods of using the same | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-03-24 | — | — | US | disclosed |
| CN-113194742-B | Antagonists of T2R54, compositions thereof and uses thereof | 弗门尼舍公司 | 2024-09-27 | — | — | CN | disclosed |
| CN-117969859-B | Metabolic biomarker for polycystic ovary syndrome and application thereof | 山东大学 | 2024-09-06 | — | — | CN | disclosed |
| CN-117969859-A | Metabolic biomarker for polycystic ovary syndrome and application thereof | 山东大学 | 2024-05-03 | — | — | CN | disclosed |
| US-20220119467-A1 | CAGED-DEGRON-BASED MOLECULAR FEEDBACK CIRCUITS AND METHODS OF USING THE SAME | UNIVERSITY OF WASHINGTON | 2022-04-21 | — | — | US | disclosed |
| US-20220119466-A1 | SYNTHETIC MOLECULAR FEEDBACK CIRCUITS AND METHODS OF USING THE SAME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-04-21 | — | — | US | disclosed |
| US-20220073565-A1 | DE NOVO DESIGN OF PROTEIN SWITCHES FOR TUNABLE CONTROL OF PROTEIN DEGRADATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-03-10 | — | — | US | disclosed |
| CN-113853384-A | Novel design of a protein switch for the tuneable control of protein degradation | 华盛顿大学 | 2021-12-28 | — | — | CN | disclosed |
| US-5302717-A | Preparation of urethane and carbonate products | MONSANTO COMPANY (US) | 1994-04-12 | — | — | US | disclosed |
| EP-0576669-A1 | NOVEL METHODS AND COMPOSITIONS FOR TREATMENT OF ANGIOGENIC DISEASES | REPLIGEN CORPORATION (US) | 1994-01-05 | — | — | EP | disclosed |
| US-5273885-A | Using a polyiodothyronine analog of a phenyl compound containing a hydroxyl group ortho to an iodine | SYNTEX (U.S.A.) INC. (US) | 1993-12-28 | — | — | US | disclosed |
| US-5260473-A | Reaction of alcohol and carbon dioxide in aprotic solvent and strong amidine or guanidine base | MONSANTO COMPANY (US) | 1993-11-09 | — | — | US | disclosed |
| EP-0556538-A1 | Blocked tricarbamate compounds | MONSANTO COMPANY (US) | 1993-08-25 | — | — | EP | disclosed |
| WO-1993013794-A1 | NOVEL METHODS AND COMPOSITIONS FOR TREATMENT OF ANGIOGENIC DISEASES | REPLIGEN CORPORATION (US) | 1993-07-22 | — | — | WO | disclosed |
| US-5223638-A | Reacting primary or secondary amine with carbon dioxide in presence of strong amidine or guanidine base to form ammonium carbamate salt, reacting in polar aprotic solvent with primary or secondary hydrocarbyl halide | MONSANTO COMPANY (US) | 1993-06-29 | — | — | US | disclosed |
| EP-0511948-A2 | Preparation of urethane and carbonate products | MONSANTO COMPANY (US) | 1992-11-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12583896-B2 | Caged-degron-based molecular feedback circuits and methods of using the same | RPRD2, STUB1, SSU72 | ALOX15 4749/4885BLM 586/4885PMP22 4594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.